Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Accumulated Expenses (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Accumulated Expenses data on record, last reported at $148.2 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $148.2 million; the TTM value through Sep 2025 reached $148.2 million, changed N/A, while the annual FY2023 figure was $6.7 million, 54.19% down from the prior year.
  • Accumulated Expenses reached $148.2 million in Q3 2025 per MIRM's latest filing, up from $127.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $148.2 million in Q3 2025 and bottomed at $5.6 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $48.7 million, with a median of $27.8 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: surged 2211.23% in 2021, then plummeted 79.84% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $10.0 million in 2021, then skyrocketed by 46.78% to $14.7 million in 2022, then tumbled by 54.19% to $6.7 million in 2023, then soared by 1409.74% to $101.4 million in 2024, then skyrocketed by 46.15% to $148.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $148.2 million in Q3 2025, $127.1 million in Q2 2025, and $101.4 million in Q2 2024.